Free Trial
ASX:DRUG

BetaShares Global Healthcare ETF - Currency Hedged (DRUG) Stock Price, News & Analysis

About BetaShares Global Healthcare ETF - Currency Hedged Stock (ASX:DRUG)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
N/A
Average Volume
N/A
Market Capitalization
A$191.74 million
P/E Ratio
N/A
Dividend Yield
3.00%
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive DRUG Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BetaShares Global Healthcare ETF - Currency Hedged and its competitors with MarketBeat's FREE daily newsletter.

DRUG Stock News Headlines

A grave, grave error.
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.
See More Headlines

DRUG Stock Analysis - Frequently Asked Questions

Based on aggregate information from My MarketBeat watchlists, some other companies that BetaShares Global Healthcare ETF - Currency Hedged investors own include Ford Motor (F), Nasstar (NASA), NVIDIA (NVDA), Netflix (NFLX), Duckhorn Portfolio (NAPA), Humana (HUM) and Google Inc. - Common Stock Ex-Distribution When Issued (GOOAV).

Industry, Sector and Symbol

Stock Exchange
ASX
Industry
Pharmaceutical Preparation Manufacturing
Sub-Industry
Pharmaceutical Products
Current Symbol
ASX:DRUG
CIK
N/A
Web
N/A
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Price / Book
N/A

Miscellaneous

Free Float
N/A
Market Cap
A$191.74 million
Optionable
Not Optionable
Beta
N/A
Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

This page (ASX:DRUG) was last updated on 7/7/2025 by MarketBeat.com Staff
From Our Partners